Bildportal.ch

Takeda Pharmaceuticals Europe Ltd
18.12.2013 - 10:01 Uhr, Takeda Pharmaceuticals Europe LtdZurich, Switzerland (ots/PRNewswire) - Demonstrates Takeda's commitment to bring new,innovative treatments to patients Takeda Pharmaceuticals International GmbH ("Takeda") today announced further expansion ofits commercial platform with the establishment of its wholly-owned subsidiary in Israel.
Together with Algeria, Ecuador, Peru, Singapore and Vietnam, Israel is the sixth salesentity Takeda has opened this year to reinforce its platform in growth markets. Takeda Israel LTD will be headquartered in the Tel Aviv area and will be responsible for thesales and marketing of selected products from Takeda's portfolio and pipeline, with aninitial focus on oncology. Takeda Israel will also seek local partners with complementaryportfolios, through which to launch additional proven medicines from its current portfolio.
Through its established network of local partners, Takeda products currently sold in Israelare Actos(R) (pioglitazone), Atacand(R) (candesartan), Contoloc(R) (pantoprazole), Lucrin(R)(leuroprelin), Xefo(R) (lornoxicam), Mepact(R) (mifamurtide) and other treatments in varioustherapeutic areas. Israel is a highly developed pharma market with a universal healthcare system that valuesinnovative medicines. The National Health Insurance constantly expands its list ofreimbursable products, having dedicated more than a third of its additional funds over thelast ten years to cancer treatment*. According to Business Monitor International,pharmaceutical sales in Israel totaled US$ 1.5 billion in 2012 and are expected to grow at acompound annual rate of 6%* between 2013 and 2017, driven by population growth and anincreased need for specialty treatments. Takeda plans to outgrow the market over the sameperiod. Arie Kramer has been appointed Country Manager for Israel. He joins from AbbVie Biopharma,where he headed Finance and Strategic Commercial Planning. Previously he had served asGeneral Manager, Chief Financial Officer and Operations Manager at Novartis Consumer Healthin Israel. "There is a growing demand for specialty treatments in Israel," said Arie Kramer, Countrymanager Takeda Israel. "The establishment of our subsidiary demonstrates our commitment tobringing innovative new medicines to patients and will enable us to address some of thecountry's current unmet healthcare needs." Patients are at the center of Takeda's approach to R&D and the Company has one of therichest and deepest pipelines in the industry today. Takeda is a global pharmaceutical company based in Japan that is poised to meet thechallenges of the constantly evolving pharmaceutical market. For more than 230 years, Takedahas been committed to serving the global community through healthcare solutions fromprevention to care to cure. Takeda is the largest pharmaceutical company in Japan and the15th largest in the world, with approximately 30,000 employees in 70 countries. TheCompany's mission is to strive toward better health for people worldwide through leadinginnovation in medicine. [*]Data Source: Data on file - Ministry of Health approved technologies list for NationalHealth Basket - 2012 About Takeda Pharmaceuticals International GmbH Headquartered in Zurich as a wholly owned subsidiary of Takeda Pharmaceutical CompanyLimited, Osaka, Japan, the company has a commercial presence covering more than 70countries, with particular strength in Asia, North America, Europe and fast-growing emergingmarkets including Latin America, Russia-CIS and China. Takeda is ranked 15th by global Rxsales, 14th in the BRIC countries and 18th in Europe Areas of focus include cardiovascularand metabolic, oncology, respiratory and immunology, central nervous system, generalmedicine, and vaccines. Takeda is a research-based global company with its main focus on pharmaceuticals. As thelargest pharmaceutical company in Japan and one of the global leaders of the industry,Takeda is committed to strive towards better health for people worldwide through leadinginnovation in medicine. Through the integration of Millennium Pharmaceuticals and Nycomed,Takeda has been transforming itself, broadening its therapeutic expertise and geographic Additional information about Takeda is available through its corporate website, This press release has been issued by Takeda Pharmaceuticals International GmbH,Thurgauerstrasse 130, CH-8152 Glattpark-Opfikon, Zurich, Switzerland. International Contact: Takeda Pharmaceuticals International GmbHBirgit Gronkowski, +41-44-555-1506, . Localcontact: Goldfinger Communications, Mahogany Levy, +972-526155308,

Source: http://www.bildportal.ch/de/pdf/100748986-takeda-launches-new-subsidiary-in-israel.pdf